Abstract
Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial and time-limited response to therapy before the cancer progresses and the patient succumbs to the disease. Despite recent advances in early diagnosis and treatment, approximately one-third of treated patients will relapse and become resistant to currently available treatments. In this review we evaluate current treatment practices and recent advances in therapy for localized prostate malignancy and advanced, metastatic prostate cancer. Some of the promising new drugs for PCa treatment include MDV3100, an androgen receptor (AR) antagonist that prevents androgens from binding to the AR and nuclear translocation and co-activator recruitment of the ligand-receptor complex; abiraterone, an orally administered drug that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17; and several newer cytotoxic drugs (epothilones, satraplatin). Key new insights are that cancer stem cells play a role in PCa and that PCa cells are dependent on the AR for proliferation, even in the hormone refractory state of the disease. We also discuss potential molecular targets for new drug candidates for the treatment of metastatic PCa.
Keywords: Androgen receptor, androgen, angiogenesis, antitumor efficacy, cancer targets, castration resistant prostate cancer, clinical trials, metastases, molecular mechanisms, multi-drug combinations, neo-adjuvant setting, Prostate cancer, therapeutic approaches
Current Medicinal Chemistry
Title: Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer
Volume: 18 Issue: 29
Author(s): R. Larsson, N. P. Mongan, M. Johansson, L. Shcherbina, P.-A. Abrahamsson, L. J. Gudas, O. Sterner and J. L. Persson
Affiliation:
Keywords: Androgen receptor, androgen, angiogenesis, antitumor efficacy, cancer targets, castration resistant prostate cancer, clinical trials, metastases, molecular mechanisms, multi-drug combinations, neo-adjuvant setting, Prostate cancer, therapeutic approaches
Abstract: Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial and time-limited response to therapy before the cancer progresses and the patient succumbs to the disease. Despite recent advances in early diagnosis and treatment, approximately one-third of treated patients will relapse and become resistant to currently available treatments. In this review we evaluate current treatment practices and recent advances in therapy for localized prostate malignancy and advanced, metastatic prostate cancer. Some of the promising new drugs for PCa treatment include MDV3100, an androgen receptor (AR) antagonist that prevents androgens from binding to the AR and nuclear translocation and co-activator recruitment of the ligand-receptor complex; abiraterone, an orally administered drug that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17; and several newer cytotoxic drugs (epothilones, satraplatin). Key new insights are that cancer stem cells play a role in PCa and that PCa cells are dependent on the AR for proliferation, even in the hormone refractory state of the disease. We also discuss potential molecular targets for new drug candidates for the treatment of metastatic PCa.
Export Options
About this article
Cite this article as:
Larsson R., P. Mongan N., Johansson M., Shcherbina L., Abrahamsson P.-A., J. Gudas L., Sterner O. and L. Persson J., Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer, Current Medicinal Chemistry 2011; 18 (29) . https://dx.doi.org/10.2174/092986711797287539
DOI https://dx.doi.org/10.2174/092986711797287539 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells
Current Drug Delivery The Promising Pharmacological Effects and Therapeutic/Medicinal Applications of Punica Granatum L. (Pomegranate) as a Functional Food in Humans and Animals
Recent Patents on Inflammation & Allergy Drug Discovery Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry Metabolic Remodeling Induced by Adipocytes: A New Achilles' Heel in Invasive Breast Cancer?
Current Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets In the Rush for Green Gold: Can Green Tea Delay Age-Progressive Brain Neurodegeneration?
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Preventive Effect of Soybean on Brain Aging and Amyloid-β Accumulation: Comprehensive Analysis of Brain Gene Expression
Recent Patents on Food, Nutrition & Agriculture Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Graphical Abstracts:
Current Radiopharmaceuticals TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients
Combinatorial Chemistry & High Throughput Screening Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs
Current Drug Therapy Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews Targeted Therapies in Non-Small Cell Lung Cancer: Proven Concepts and Unfulfilled Promises.
Current Cancer Drug Targets Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry